This variant is expressed on 40% of SCCHN tumors and is responsible for increased proliferation, tumor growth, and chemotherapy resistance to antitumor drugs including the EGFR targeting moAb cetuximab [3]. The gene discussed is EGFR; the disease is neoplasm.